Although further pre-clinical or clinical studies and statistical analysis are needed, our findings not only provide a route to reduce the cyto-toxicity of DDP during neoadjuvant or adjuvant chemotherapy59, but also provide a potential therapeutic strategy to improve the clinical outcome of YTHDF1 low expressing NSCLC patients, by combining usage of AKR1C1 specific (pre-) clinical inhibitors with platinum based chemotherapy in future. The gene discussed is AKR1C1; the disease is non-small cell lung carcinoma.